Uncommon Presentation of Multiple Myeloma: Pleural Effusion and Extensive Extramedullary Involvement
Multiple Myeloma with EMD and Pleural Effusion Response
Abstract
A 60-year-old female presented with abdominal pain, weight loss, and fatigue. Imaging revealed a pancreatic mass, bilateral pleural effusion, ascites, and lytic bony lesions. Investigations confirmed multiple myeloma with lambda light chain disease. Positron emission tomography-computed tomography (PET-CT) scan demonstrated extensive metabolically active soft tissue masses involving the pancreatic region, retroperitoneum, mediastinum, paravertebral regions, and multiple skeletal lesions with extraosseous soft tissue involvement, along with bilateral pleural effusions with metabolically active pleural and extrapleural deposits. The patient was initiated on a bortezomib, cyclophosphamide, and dexamethasone chemotherapy regimen with therapeutic thoracentesis for pleural effusion management. After two cycles, the patient showed remarkable clinical improvement. A repeat PET-CT scan revealed significant interval regression of soft tissue masses, metabolic activity resolution, and regression of pleural and extrapleural deposits. The extensive skeletal lytic lesions showed morphological stability but regression of associated metabolic activity and extraosseous soft tissue. This case highlights the potential of novel agent-based regimens in achieving exceptional responses in multiple myeloma patients with extensive extramedullary disease (EMD), including uncommon manifestations like pleural effusion. Early recognition and prompt initiation of appropriate therapy are crucial for improving outcomes in such cases.
2. Iqbal N, Tariq MU, Shaikh MU, et al. Pleural effusion as a manifestation of multiple myeloma. BMJ Case Rep. 2016;2016:bcr2016215433.
3. Ramos AL, Trindade M, Santos Pinto A, et al. Pleural effusion and multiple myeloma - more than meets the eye: A case report. Mol Clin Oncol. 2021;15(5):238.
4. Bansal R, Rakshit S, Kumar S. Extramedullary disease in multiple myeloma. Blood Cancer J. 2021;11(9):161.
5. Miller J, Alton PA. Myelomatous pleural effusion-A case report. Respir Med Case Rep. 2012;5:59–61.
6. Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325–330.
7. Reddy PV, Singh V, Roy R, et al. Multiple myeloma presenting as clival mass: a diagnostic delimma. BMJ Case Rep . 2021;14(3):e240670.
8. Alkan O, Tiryaki TO , Kalayoglu-Besisik S. Myelomatous Pleural Effusion: A Rare Involvement in Myeloma. J Med Cases. 2020 Mar;11(3):55-56.
9. Weinstock M, Aljawai Y, Morgan EA, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169(6):851–8.
10. Chen D, Frezza M, Schmitt S, et al. Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives. Curr Cancer Drug Targets. 2011;11(3):239–53.
11. Alkylating Agent - an overview | ScienceDirect Topics [Internet]. [cited 2024 Jul 25]. Available from: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/alkylating-agent.
12. Giles AJ, Hutchinson MKND, Sonnemann HM, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018; 6: 51.
13. Cavo M, Gay F, Beksac M, et al. Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. Blood. 2020;136(Supplement 1):37–8.
Files | ||
Issue | Vol 18 No 4 (2024) | |
Section | Case Report(s) | |
DOI | https://doi.org/10.18502/ijhoscr.v18i4.16766 | |
Keywords | ||
Multiple myeloma; Extramedullary disease; Pleural effusion; Bortezomib; Positron emission tomography-computed tomography (PET-CT) |
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |